Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Darusentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB known ✓ | P24530 | 20/20 | 1.00 |
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.74 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darusentan SCHEMBL1068546 | 1.00 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL7934042 | 0.93 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL13066899 | 0.93 | EDNRB (0.86) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL8021756 | 0.92 | EDNRB (0.86) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL2350734 | 0.90 | EDNRB (0.81) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL1068402 | 0.90 | EDNRB (0.81) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Darusentan SCHEMBL6895168 | 0.89 | EDNRB (0.80) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Darusentan SCHEMBL14026681 | 0.88 | EDNRB (0.78) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL7071036 | 0.88 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL15999837 | 0.87 | EDNRB (0.76) | EDNRBEDNRANR1I2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2024-08-20 | — | — | US | claimed |
| WO-2024102699-A1 | GUANYLATE CYCLASE (GC) STIMULATOR FORMULATIONS AND USES THEREOF | ELANCO US, Inc. (US) | 2024-05-16 | — | — | WO | claimed |
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | ADVERIO PHARMA GMBH (DE) | 2022-12-29 | — | — | US | claimed |
| WO-2022198259-A1 | TREATMENT METHODS FOR PULMONARY ARTERIAL HYPERTENSION | THE HEART RESEARCH INSTITUTE LTD (AU) | 2022-09-29 | — | — | WO | claimed |
| US-11439642-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2022-09-13 | — | — | US | claimed |
| EP-3169365-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | Westfälische Wilhelms-Universität Münster (DE) | 2017-05-24 | — | — | EP | claimed |
| WO-2015169884-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2015-11-12 | — | — | WO | claimed |
| US-20110263854-A1 | Improved Process For The Preparation Of Endothelin Receptor Antagonists | MSN LABORATORIES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| EP-2350024-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS | MSN Laboratories Limited (IN) | 2011-08-03 | — | — | EP | claimed |
| WO-2010070658-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS | MSN LABORATORIES LIMITED (IN) | 2010-06-24 | — | — | WO | claimed |
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | claimed |
| EP-1289558-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-12 | — | — | EP | claimed |
| WO-2001091736-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | claimed |
| US-12606631-B2 | Antibodies which bind human endothelin receptor a (ETAR) | REMD BIOTHERAPEUTICS INC (US) | 2026-04-21 | — | — | US | disclosed |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2026-04-07 | — | — | US | disclosed |
| EP-4715043-A1 | METHOD FOR PRODUCING NEURAL CREST CELLS | Kyoto University (JP) | 2026-03-25 | — | — | EP | disclosed |
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | disclosed |
| WO-2003031447-A2 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2003-04-17 | — | — | WO | disclosed |
| EP-1289558-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001091736-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | EDNRB 689/4885EDNRA 423/4885NR1I2 1233/4885 |
| US-11439642-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | EDNRB 689/4885EDNRA 423/4885NR1I2 1233/4885 |
| US-12606631-B2 | Antibodies which bind human endothelin receptor a (ETAR) | EDNRA, EDNRB, FCGR2A | EDNRB 2/4885EDNRA 1/4885NR1I2 706/4885 |
| US-20110263854-A1 | Improved Process For The Preparation Of Endothelin Receptor Antagonists | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885NR1I2 2109/4885 |
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885NR1I2 773/4885 |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | SSB, PDK4, FPR1 | EDNRB 341/4885EDNRA 316/4885NR1I2 3086/4885 |
| US-20220409618-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE | PFKP, PON1, FABP3 | EDNRB 689/4885EDNRA 423/4885NR1I2 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.